GLIS3蛋白在三阴性乳腺癌中的表达及其对患者预后的影响

李晨浩; 刘月平; 李春晓; 崔国忠; 黄徐晨; 张乙; 张国宇; 耿翠芝

doi:10.16016/j.2097-0927.202401005

您当前的位置：

首页 >

文章列表页 >

GLIS3蛋白在三阴性乳腺癌中的表达及其对患者预后的影响

临床医学 | 更新时间：2026-01-09

- GLIS3蛋白在三阴性乳腺癌中的表达及其对患者预后的影响
- Expression of GLIS3 protein in triple negative breast cancer and its influence on prognosis of patients
- 陆军军医大学学报 2024年46卷第13期页码：1553-1560
- 作者机构：
  
  1.061000 河北沧州，沧州市中心医院甲乳外二科
  2.050000 石家庄，河北医科大学第四医院病理科
  3.050000 石家庄，河北医科大学第四医院乳腺中心
  4.050000 石家庄，河北医科大学第四医院河北省乳腺癌分子医学重点实验室
  5.050000 石家庄，河北医科大学第四医院河北省肿瘤预防和精准诊疗重点实验室
- 作者简介：
  
  [ 耿翠芝，E-mail: gengcuizhisci@163.com GENG Cuizhi, E-mail: gengcuizhisci@163.com
- 基金信息：
  
  河北省自然科学基金(H2020206199);作者贡献声明李晨浩参与实验设计、实验实施及撰写论文；刘月平、李春晓、崔国忠参与实验评估；黄徐晨、张乙、张国宇参与实验实施；耿翠芝参与实验设计及论文审校
- DOI：10.16016/j.2097-0927.202401005
  中图分类号： R394.3;R730.7;R737.9
- 收稿：2024-01-03，
  
  修回：2024-04-04，
  
  纸质出版：2024-07-15
- 稿件说明：
移动端阅览
李晨浩, 刘月平, 李春晓, 等. GLIS3蛋白在三阴性乳腺癌中的表达及其对患者预后的影响[J]. 陆军军医大学学报, 2024,46(13):1553-1560.

Chenhao LI, Yueping LIU, Chunxiao LI, et al. Expression of GLIS3 protein in triple negative breast cancer and its influence on prognosis of patients[J]. Journal of Army Medical University, 2024, 46(13): 1553-1560.
李晨浩, 刘月平, 李春晓, 等. GLIS3蛋白在三阴性乳腺癌中的表达及其对患者预后的影响[J]. 陆军军医大学学报, 2024,46(13):1553-1560. DOI： 10.16016/j.2097-0927.202401005.

Chenhao LI, Yueping LIU, Chunxiao LI, et al. Expression of GLIS3 protein in triple negative breast cancer and its influence on prognosis of patients[J]. Journal of Army Medical University, 2024, 46(13): 1553-1560. DOI： 10.16016/j.2097-0927.202401005.

摘要

目的

观察GLIS3蛋白在三阴性乳腺癌(triple negative breast cancer，TNBC)组织中的表达水平，分析其与三阴性乳腺癌患者预后的关系。

方法

运用生物信息学方法分析基因表达综合数据库(Gene Expression Omnibus，GEO)中GLIS3的表达水平；根据DNA芯片数据，采用Kaplan-Meier生存曲线分析GLIS3的表达对患者生存率的影响。通过整群随机抽样法选取2014年1－12月在河北医科大学第四医院乳腺中心就诊并经病理确诊为TNBC的患者125例。纳入组织标本完好、病历资料完备以及随访资料完全的53例患者。通过免疫组化染色分析GLIS3在TNBC以及癌旁乳腺组织中的表达，同时分析GLIS3蛋白在乳腺癌组织中的表达与乳腺癌患者的年龄、月经周期、肿瘤大小、临床阶段、组织学评级、病理种类、腋窝淋巴结转移、脉管瘤栓、TP53、Ki-67等临床病理学参数之间的联系。利用Kaplan-Meier生存曲线分析GLIS3对三阴性乳腺癌患者的无病生存期和总生存期的影响。利用Cox回归模型分析影响三阴性乳腺癌患者预后的风险因素。

结果

GSE76275数据库解析结果发现，GLIS3在TNBC中的表达高于癌旁组织(

0.05)。与癌旁乳腺组织比较，TNBC组织中GLIS3蛋白表达明显升高(

0.05)。在肿瘤分期较高、体积较大的患者中GLIS3的表达显著升高(

0.05)。Cox回归模型的单因素分析发现，三阴性乳腺癌患者的无病生存期与其淋巴结转移、TNM分期以及GLIS3的表达量相关(

0.05)；单因素和多因素分析结果均显示，三阴性乳腺癌患者的总生存期与TNM分期相关(

0.05)。GLIS3高表达的患者，无病生存期明显低于GLIS3低表达的患者(

＜0.05)，而总生存期与GLIS3低表达的患者差异无统计学意义。

结论

GLIS3蛋白在TNBC组织中高表达，肿瘤大小和TNM分期与GLIS3的高表达有关，GLIS3蛋白高表达提示患者预后不良、无病生存率低。

Abstract

Objective

To observe the expression of GLIS3 in triple negative breast cancer (TNBC) and analyze its relationship with the prognosis of TNBC patients.

Methods

Bioinformatic analysis was applied to analyze the expression level of GLIS3 in Gene Expression Omnibus (GEO). Kaplan-Meier survival curve was plotted to evaluate the impact of GLIS3 expression on the survival rate of patients based on DNA chip data. A total of 125 patients pathologically diagnosed as TNBC in the Fourth Hospital of Hebei Medical University from January to December 2014 were enrolled by cluster random sampling. Among them

53 patients had complete tissue specimens

medical records and follow-up data. Immunohistochemical assay was used to detect the expression of GLIS3 in TNBC and adjacent tissues to tumors

while the relationships between GLIS3 protein expression in breast cancer tissues and clinicopathological parameters such as age

menstrual status

tumor size

clinical stage

histological grade

pathological type

axillary lymph node metastasis

vascular tumor thrombus

and expression of TP53 and Ki-67 were analyzed. Kaplan-Meier survival curve was plotted to analyze the effect of GLIS3 on the overall and disease-free survival of TNBC patients. Cox regression model was established to identify the risk factors impacting the prognosis of the patients.

Results

Analysis of GEO data showed that the expression of GLIS3 in TNBC was significantly higher than that in paracancer tissues (

0.05). The expression of GLIS3 was notably higher in the TNBC tissue than the adjacent tissue to tumor (

0.05). A marked augmentation of GLIS3 expression was observed in both the advanced and larger-sized tumors (

0.05). Univariate analysis of Cox regression model revealed that lymph node metastasis

TNM stage and GLIS3 expression were all related to disease-free survival of TNBC patients (

0.05). Univariate and multivariate analyses displayed that TNM stage was related to the overall survival of TNBC patients (

0.05). The patients with high expression of GLIS3 had significant shorter disease-free survival time than those with low expression (

0.05)

but had no statistical difference in overall survival (

0.05).

Conclusion

GLIS3 protein is highly expressed in TNBC tissues

and tumor size and TNM stage are correlated with its high expression. The high expression of GLIS3 suggests that the patients have poor prognosis and low disease-free survival rate.

关键词

Keywords

references

NIK-ZAINAL S, DAVIES H, STAAF J, et al . Landscape of somatic mutations in 560 breast cancer whole-genome sequences[J ] . Nature, 2016, 534(7605): 47-54. DOI: 10.1038/nature17676.

XIA C F, DONG X S, LI H, et al . Cancer statistics in China and United States, 2022: profiles, trends and determinants[J ] . Chin Med J(Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108.

VAGIA E, MAHALINGAM D, CRISTOFANILLI M. The landscape of targeted therapies in TNBC[J]. Cancers, 2020, 12(4): 916. DOI: 10.3390/cancers12040916.

董文磊, 程巧, 甘露. T 2 N 0 M 0 三阴性乳腺癌患者复发的危险因素及不同局部治疗方案对预后的影响[J ] . 肿瘤学杂志, 2023, 29(3): 198-202. DOI: 10.11735/j.issn.1671-170X.2023.03.B005..

DONG W L, CHENG Q, GAN L. Risk factors of recurrence and prognosis in patients of T 2 N 0 M 0 tride-negative breast cancer undergoing different therapeutic modalities[J ] . J Chin Oncol, 2023, 29(3): 198-202. DOI: 10.11735/j.issn.1671-170X.2023.03.B005..

张正品, 裴斐, 金建芳, 等. 超声诊断在三阴性乳腺癌诊断中的临床意义[J]. 长治医学院学报, 2023, 37(1): 36-39. DOI: 10.3969/j.issn.1006-0588.2023.01.009.

ZHANG Z P, PEI F, JIN J F, et al . Clinical significance of ultrasound in the diagnosis of triple-negative breast cancer[J ] . J Changzhi Med Coll, 2023, 37(1): 36-39. DOI: 10.3969/j.issn.1006-0588.2023.01.009.

WON K A, SPRUCK C. Triple-negative breast cancer therapy: current and future perspectives (Review)[J]. Int J Oncol, 2020, 57(6): 1245-1261. DOI: 10.3892/ijo.2020.5135.

史超, 张香梅, 刘运江. 三阴性乳腺癌免疫及靶向治疗研究进展[J]. 肿瘤防治研究, 2023, 50(7): 710-716. DOI: 10.3971/j.issn.1000-8578.2023.22.1426.

SHI C, ZHANG X M, LIU Y J. Research progress on immunization and targeted therapy for triple-negative breast cancer[J]. Cancer Res Prev Treat, 2023, 50(7): 710-716. DOI: 10.3971/j.issn.1000-8578.2023.22.1426.

阎红, 支欣. 三阴性乳腺癌治疗有新策略[N]. 健康报, 2023-06-21(6).

YAN H, ZHI X. New treatment strategy for triple negative breast cancer[N]. Health News, 2023-06-21(6).

PINTO K, CHETTY R. Gene of the month: GLIS 1-3[J ] . J Clin Pathol, 2020, 73(9): 527-530. DOI: 10.1136/jclinpath-2020-206859.

YUSENKO M V, KOVACS G. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma[J]. Histopathology, 2009, 55(6): 687-695. DOI: 10.1111/j.1365-2559.2009.03449.x.

LUKASHOVA-V ZANGEN I, KNEITZ S, MONORANU C M, et al . Ependymoma gene expression profiles associated with histological subtype, proliferation and patient survival[J ] . Acta Neuropathol, 2007, 113(3): 325-337. DOI: 10.1007/s00401-006-0190-5.

JAYACHANDRAN A, PRITHVIRAJ P, L O P H, et al . Identifying and targeting determinants of melanoma cellular invasion[J ] . Oncotarget, 2016, 7(27): 41186-41202. DOI: 10.18632/oncotarget.9227.

RAMI F, BARADARAN A, KAHNAMOOI M M, et al . Alteration of GLIS 3 gene expression pattern in patients with breast cancer[J ] . Adv Biomed Res, 2016, 5: 44. DOI: 10.4103/2277-9175.178803..

ZAGAMI P, CAREY L A. Triple negative breast cancer: pitfalls and progress[J]. NPJ Breast Cancer, 2022, 8(1): 95. DOI: 10.1038/s41523-022-00468-0.

LICHTI-KAISER K, ZERUTH G, KANG H S, et al . Gli-similar proteins: their mechanisms of action, physiological functions and roles in disease[J ] . Vitam Horm, 2012, 88: 141-171. DOI: 10.1016/B978-0-12-394622-5.00007-9.

JETTEN A M. Emerging roles of GLI-similar Krüppel-like zinc finger transcription factors in leukemia and other cancers[J]. Trends Cancer, 2019, 5(9): 547-557. DOI: 10.1016/j.trecan.2019.07.005.

ZHANG Y, WANG B, SONG H, et al . GLIS3, a novel prognostic indicator of gastric adenocarcinoma, contributes to the malignant biological behaviors of tumor cells via modulating TGF-β1/TGFβR1/Smad1/5 signaling pathway[J ] . Cytokine, 2023, 170: 156342. DOI: 10.1016/j.cyto.2023.156342..

ZHANG Y X, WANG X F, LIU W W, et al . CircGLIS3 promotes gastric cancer progression by regulating the miR-1343-3p/PGK1 pathway and inhibiting vimentin phosphorylation[J ] . J Transl Med, 2024, 22(1): 251. DOI: 10.1186/s12967-023-04625-2.

HIROKAWA M, MATSUSE M, MITSUTAKE N, et al . Non-hyalinizing trabecular thyroid adenoma: a novel thyroid tumor with diagnostic pitfalls of hyalinizing trabecular adenoma and medullary thyroid carcinoma[J ] . Diagn Pathol, 2023, 18(1): 74. DOI: 10.1186/s13000-023-01361-5.

MAHJABIN F, GONSALVES C, DREW P A, et al . Understanding and overcoming the pitfalls in cytopathological diagnosis of hyalinizing trabecular tumor of thyroid[J ] . Int J Surg Pathol, 2024, 32(1): 91-96. DOI: 10.1177/10668969231166295.

AL-TEMAIMI R A, TAN T Z, MARAFIE M J, et al . Identification of 42 genes linked to stage Ⅱ colorectal cancer metastatic relapse[J ] . Int J Mol Sci, 2016, 17(5): 598. DOI: 10.3390/ijms17050598.

KUMARI M, KRISHNAMURTHY P T, PINDUPROLU S K S S, et al . DR-5 and DLL-4 MAb functionalized SLNs of gamma-secretase inhibitors- an approach for TNBC treatment[J ] . Adv Pharm Bull, 2021, 11(4): 618-623. DOI: 10.34172/apb.2021.070.

徐博文, 畅建平, 魏志成, 等. 影响胆囊癌病人R0切除术后远期疗效的危险因素及治疗策略分析[J]. 中国实用外科杂志, 2023, 43(11): 1258-1266. DOI: 10.19538/j.cjps.issn1005-2208.2023.11.14.

XU B W, CHANG J P, WEI Z C, et al . Analysis of prognostic factors and treatment strategies affecting long-term efficacy of R0 resection in patients with gallbladder cancer[J ] . Chin J Pract Surg, 2023, 43(11): 1258-1266. DOI: 10.19538/j.cjps.issn1005-2208.2023.11.14.

HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013.

王瑞, 马腾达, 屈才浩, 等. 基于生物信息学分析GLIS3在胃癌中表达与免疫浸润的临床意义[J]. 重庆医学, 2022, 51(17): 3003-3009, 3015. DOI: 10.3969/j.issn.1671-8348.2022.17.027.

WANG R, MA T D, QU C H, et al . Clinical significance of GLIS3 expression and immune infiltration in gastric cancer based on bioinformatics analysis[J ] . Chongqing Med, 2022, 51(17): 3003-3009, 3015. DOI: 10.3969/j.issn.1671-8348.2022.17.027.

PERKINS N D. The diverse and complex roles of NF-κB subunits in cancer[J]. Nat Rev Cancer, 2012, 12(2): 121-132. DOI: 10.1038/nrc3204.

XU L, HAZARD F K, ZMOOS A F, et al . Genomic analysis of fibrolamellar hepatocellular carcinoma[J ] . Hum Mol Genet, 2015, 24(1): 50-63. DOI: 10.1093/hmg/ddu418.

DIDONATO J A, MERCURIO F, KARIN M. NF-κB and the link between inflammation and cancer[J]. Immunol Rev, 2012, 246(1): 379-400. DOI: 10.1111/j.1600-065X.2012.01099.

浏览量

132

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

拉米夫定对慢性重型乙型肝炎患者生存率的提高

基于中国人群的雌激素受体表达新分层（低/中/高）可更精准地预测HR⁺/HER2^-早期乳腺癌患者的预后

转录因子TGIF1高表达胃癌的免疫抑制性微环境特征及临床意义分析

核仁磷酸蛋白1突变的分子异质性对急性髓系白血病预后的影响